BR112017027448A2 - vacina contra rsv - Google Patents

vacina contra rsv

Info

Publication number
BR112017027448A2
BR112017027448A2 BR112017027448A BR112017027448A BR112017027448A2 BR 112017027448 A2 BR112017027448 A2 BR 112017027448A2 BR 112017027448 A BR112017027448 A BR 112017027448A BR 112017027448 A BR112017027448 A BR 112017027448A BR 112017027448 A2 BR112017027448 A2 BR 112017027448A2
Authority
BR
Brazil
Prior art keywords
mutation
rsv
amino acid
polypeptide
fusion
Prior art date
Application number
BR112017027448A
Other languages
English (en)
Inventor
André Emmy Roymans Dirk
Langedijk Johannes
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112017027448A2 publication Critical patent/BR112017027448A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a composições compreendendo um polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) recombinante que é estabilizado na conformação pré-fusão, em que o referido polipeptídeo (rsv) (f) compreende pelo menos uma mutação em comparação com um polipeptídeo (rsv) (f) de tipo selvagem, em que a pelo menos uma mutação é selecionada do grupo consistindo de: a) uma mutação do aminoácido ácido aspártico (d) na posição 486, b) uma mutação do aminoácido ácido aspártico (d) na posição 489 e c) uma mutação do aminoácido serina (s) na posição 398 e/ou do aminoácido lisina (k) na posição 394. a invenção também refere-se a composições compreendendo uma molécula de ácido nucleico isolado codificando os referidos polipeptídeos (rsv) (f) estáveis.
BR112017027448A 2015-07-07 2016-07-07 vacina contra rsv BR112017027448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175647 2015-07-07
PCT/EP2016/066098 WO2017005844A1 (en) 2015-07-07 2016-07-07 Vaccine against rsv

Publications (1)

Publication Number Publication Date
BR112017027448A2 true BR112017027448A2 (pt) 2018-09-04

Family

ID=53539547

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027448A BR112017027448A2 (pt) 2015-07-07 2016-07-07 vacina contra rsv

Country Status (16)

Country Link
US (3) US10456462B2 (pt)
EP (2) EP3319633B1 (pt)
JP (1) JP7189014B2 (pt)
KR (1) KR102638978B1 (pt)
CN (2) CN116059336A (pt)
AU (2) AU2016289492B2 (pt)
BR (1) BR112017027448A2 (pt)
CA (1) CA2991002C (pt)
DK (1) DK3319633T3 (pt)
EA (1) EA039065B1 (pt)
ES (1) ES2839880T3 (pt)
HK (1) HK1250939A1 (pt)
IL (2) IL288541B (pt)
PL (1) PL3319633T3 (pt)
WO (1) WO2017005844A1 (pt)
ZA (1) ZA201800092B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
EP3624844A1 (en) * 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200138234A (ko) 2018-02-28 2020-12-09 유니버시티 오브 워싱톤 자기 조립 나노구조 백신
KR20210091749A (ko) * 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
KR20220164543A (ko) 2020-04-02 2022-12-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 백신 조성물
CA3207841A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc Fimh mutants, compositions therewith and use thereof
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN117986382A (zh) * 2022-11-04 2024-05-07 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US17543A (en) * 1857-06-09 Improvement in power printing-presses
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ES2272053T3 (es) 1998-02-17 2007-04-16 Schering Corporation Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE485382T1 (de) 1999-05-17 2010-11-15 Crucell Holland Bv Rekombinantes adenovirus des ad26-serotyps
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6281823B1 (en) 1999-09-21 2001-08-28 Agere Systems Guardian Corp. Direct digital synthesis using a sine weighted DAC
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
CA2415688A1 (en) 2000-05-08 2001-11-15 Anand Rao Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) * 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
RU2004125283A (ru) 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) Стабилизированные композиции аденовируса
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
EP1783212B1 (en) 2002-05-14 2011-01-05 Merck Sharp & Dohme Corp. Methods of adenovirus purification
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US20090110695A1 (en) 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
EP4219566A3 (en) 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
EP2257809B1 (en) 2008-02-29 2012-02-08 Tibotec Pharmaceuticals Method for identifying inhibitors against viruses that use a class i fusion protein
US8225289B2 (en) 2008-03-04 2012-07-17 Wind River Systems, Inc. Method and system for improved tool interaction with a target
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
CN101464897A (zh) 2009-01-12 2009-06-24 阿里巴巴集团控股有限公司 一种词匹配及信息查询方法及装置
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
EA201270062A1 (ru) 2009-06-24 2013-02-28 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Вакцина
US9492531B2 (en) 2009-06-24 2016-11-15 Glaxosmithkline Biologicals Sa Recombinant RSV vaccines
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
KR101778317B1 (ko) 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법
KR101749779B1 (ko) 2009-10-15 2017-06-21 크루셀 홀란드 비.브이. 아데노바이러스 입자의 정제 방법
DK2488635T3 (en) 2009-10-15 2014-02-24 Crucell Holland Bv A method for purifying adenovirus of cultures with high cell density
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
EP2534135A2 (en) 2010-02-12 2012-12-19 KRKA, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
WO2012003466A1 (en) 2010-07-02 2012-01-05 Ensysce Biosciences, Inc. Single-walled carbon nanotube/sirna complexes and methods related thereto
BR112012031638B1 (pt) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
US8317672B2 (en) 2010-11-19 2012-11-27 Kensey Nash Corporation Centrifuge method and apparatus
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
BR112014023196B1 (pt) 2012-03-22 2021-09-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
WO2014077096A1 (ja) 2012-11-15 2014-05-22 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
CA2902877A1 (en) * 2013-03-13 2014-10-02 Jeffrey Boyington Prefusion rsv f proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CA2904758A1 (en) 2013-03-14 2014-09-25 Peroxyium, Inc., Delaware C Corp. Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceo2 particles via nano-encapsulation and coating
US10035842B2 (en) 2013-04-15 2018-07-31 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
EA035861B1 (ru) 2013-04-15 2020-08-21 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
ME03324B (me) 2013-09-19 2019-10-20 Janssen Vaccines & Prevention Bv Poboljšanje adenovirusnih formulacija
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
JP6350376B2 (ja) 2015-04-23 2018-07-04 住友金属鉱山株式会社 非水系電解質二次電池用正極活物質及びその製造方法、並びにその正極活物質を用いた非水系電解質二次電池
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
MA43763B1 (fr) 2016-04-05 2021-03-31 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US10522129B2 (en) 2016-10-06 2019-12-31 Gopro, Inc. Active acoustic and vibration noise canceling in waterproof camera
KR20180056310A (ko) 2016-11-18 2018-05-28 삼성전자주식회사 복합양극활물질, 이를 채용한 양극과 리튬전지 및 그 제조방법
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
KR20210091749A (ko) 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
MX2021012991A (es) 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Antigenos de gripe recombinantes.
CN113924113A (zh) 2019-05-15 2022-01-11 扬森疫苗与预防公司 季节性流感疫苗与基于腺病毒的呼吸道合胞病毒疫苗的共同施用
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
KR20220164543A (ko) 2020-04-02 2022-12-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 백신 조성물
CA3188170A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection

Also Published As

Publication number Publication date
IL256561A (en) 2018-06-28
CA2991002A1 (en) 2017-01-12
EP3821906A1 (en) 2021-05-19
CN116059336A (zh) 2023-05-05
AU2016289492A1 (en) 2018-03-01
US20200061183A1 (en) 2020-02-27
EA201890220A1 (ru) 2018-06-29
IL288541B (en) 2022-08-01
EP3319633B1 (en) 2020-11-11
DK3319633T3 (da) 2021-02-01
AU2022268296A1 (en) 2022-12-15
US11998597B2 (en) 2024-06-04
US10456462B2 (en) 2019-10-29
ES2839880T3 (es) 2021-07-06
IL288541A (en) 2022-02-01
HK1250939A1 (zh) 2019-01-18
KR20180027560A (ko) 2018-03-14
CN107847580B (zh) 2022-08-12
PL3319633T3 (pl) 2021-04-19
US20220125912A1 (en) 2022-04-28
WO2017005844A1 (en) 2017-01-12
IL256561B (en) 2022-01-01
EP3319633A1 (en) 2018-05-16
US11229694B2 (en) 2022-01-25
EA039065B1 (ru) 2021-11-29
KR102638978B1 (ko) 2024-02-22
JP2018520159A (ja) 2018-07-26
AU2016289492B2 (en) 2022-08-11
ZA201800092B (en) 2021-07-28
CN107847580A (zh) 2018-03-27
JP7189014B2 (ja) 2022-12-13
US20180200360A1 (en) 2018-07-19
CA2991002C (en) 2023-11-28

Similar Documents

Publication Publication Date Title
BR112017027448A2 (pt) vacina contra rsv
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
BR112017019625A2 (pt) udp-glicosiltransferases
EA201892250A1 (ru) Вакцина против rsv
BR112019004189A2 (pt) trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
BR112018003665A2 (pt) métodos e composições para vetores virais de evasão de anticorpo
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112018076215A2 (pt) partículas e composições de nicotina
BR112016013138A2 (pt) mistura de peptídeos
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
BR112017020308A2 (pt) udp-glicosiltransferases
BR112015029635A2 (pt) polipeptídeo do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, e, composição
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
BR112018073681A2 (pt) análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
EA201892554A1 (ru) Мутант cd200 и его применения
EA201792362A8 (ru) Композиции и способы для лечения целиакии спру
BR112018010887A2 (pt) polipeptídeo de fusão
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]